News Headlines

  1. Atossa Genetics Completes Enrollment In Endoxifen Phase 1 Study And Provides Update On Fulvestrant Microcatheter Phase 2 Study
    7/25/2017

    Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, has now completed enrollment in its Phase 1 dose escalation study of Atossa's proprietary Endoxifen

  2. Patent For Enhancing Immunotherapy In Cancer Treatment Granted To Galectin Therapeutics
    7/25/2017

    Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Method of Enhancing Specific Immunotherapies in Cancer Treatment"

  3. VALNEVA Receives FDA Fast Track Designation For Its Lyme Disease Vaccine Candidate VLA15
    7/25/2017

    Valneva SE ("Valneva" or "the Company"), a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines, recently announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its Lyme disease vaccine candidate VLA15.

  4. Retrophin Commences Patient Dosing In International, Registrational Phase 3 Trial Of RE-024 In PKAN
    7/25/2017

    Retrophin, Inc. (NASDAQ:RTRX) today announced that the first patient has been dosed in the FORT (FOsmetpantotenate Replacement Therapy) Study, an international, registrational Phase 3 clinical trial assessing the safety and efficacy of RE-024 (fosmetpantotenate) for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), a rare, genetic neurological disorder.

  5. Tetraphase Announces Positive Top-Line Results From Phase 3 IGNITE4 Clinical Trial In Complicated Intra-Abdominal Infections
    7/25/2017

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced positive top-line results from IGNITE4, the Company's phase 3 clinical trial evaluating the efficacy and safety of twice-daily intravenous (IV) eravacycline compared to meropenem for the treatment of patients with complicated intra-abdominal infections (cIAI).

  6. Santen And TRACON Announce Initiation Of A Phase 2a Study Of Wet Age-Related Macular Degeneration
    7/25/2017

    Santen Pharmaceutical Co. Ltd. (Santen) and TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) (TRACON) today announced that Santen has initiated a Phase 2a clinical study of DE-122 in patients with wet age-related macular degeneration (AMD).

  7. Pacira Announces Topline Phase 3 Results For EXPAREL® As A Single-Dose Nerve Block
    7/25/2017

    Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the completion of two Phase 3 placebo-controlled studies evaluating the efficacy, safety and pharmacokinetics of EXPAREL® (bupivacaine liposome injectable suspension) as a single-dose nerve block for prolonged regional analgesia.

  8. TrialKit™ Allows Researchers To Easily Employ Core Motion And HealthKit™ On iPhone® And Apple Watch® In Clinical Trials
    7/20/2017

    Crucial Data Solutions (CDS) is excited to announce a real solution to make clinical trial sites and study participants truly unified. TrialKit, a native mobile app, empowers investigators and clinicians to build, deploy, and manage regulatory compliant (FDA 21 CFR Part 11) research studies entirely on mobile devices.

  9. Celyad Announces Initiation Of The SHRINK Trial
    7/20/2017

    Celyad SA/NV (EURONEXT Brussels:CYAD) (EURONEXT Paris:CYAD) (NASDAQ:CYAD), a leader in the discovery and development of CAR-T cell therapies, today announced the initiation of the SHRINK trial, a third clinical trial with its lead product candidate CYAD-01 (CAR-T NKG2D), targeting metastatic colorectal patients.

  10. Kamada Submits Proposed Phase 3 Protocol To FDA For Inhaled Alpha-1 Antitrypsin For Treatment Of Alpha-1 Antitrypsin Deficiency Disease
    7/20/2017

    Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy (Inhaled AAT) for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).